FDA gives sped-up review to Novartis’ sickle cell disease drug
The FDA granted priority review to crizanlizumab as a treatment for preventing painful, life-threatening events in sickle cell disease patients.
The FDA granted priority review to crizanlizumab as a treatment for preventing painful, life-threatening events in sickle cell disease patients.